drugset / Trial / NCT06904807
A Phase I Study to Evaluate LIFE-001
RandomizedParallel-groupDouble-blindTreatment
Summary
The goal of this clinical trial is to learn if LIFE-001 is safe and tolerable for healthy adult volunteers.
Timeline
- Start
- 2025-04-07
- Primary completion
- 2026-11-13
- Completion
- 2026-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LIFE-001 | Unknown | 10 mg | Subcutaneous |
| Subject | LIFE-001 | Unknown | 50 mg | Subcutaneous |
| Subject | LIFE-001 | Unknown | 1500 mg | Subcutaneous |
Indications
No indication recorded.